Korro Bio Executives Stack Up Zero‑Cost Options, Betting on a Near‑Term Pipeline Upswing
Insider buying spurs optimism at Korro Bio: COO & execs lock in $1.2 M in zero‑cost options, signaling confidence in RNA‑therapy pipeline and upside potential.
4 minutes to read